Japan Tissue Engineering Co., Ltd. (TYO:7774)
637.00
-11.00 (-1.70%)
Nov 18, 2026, 10:20 AM JST
Japan Tissue Engineering Revenue
Japan Tissue Engineering had revenue of 732.18M JPY in the quarter ending September 30, 2026, with 28.00% growth. This brings the company's total for the last twelve months to 2.68B, up 17.06% year-over-year. In the fiscal year ending March 31, 2026, Japan Tissue Engineering had annual revenue of 2.18B, down -11.12%. That makes Japan Tissue Engineering the 34,871st largest company in the world by revenue and 3,565th in Japan.
Revenue (ttm)
2.68B
Revenue Growth
+17.06%
P/S Ratio
9.81
Revenue / Employee
13.42M
Employees
200
Market Cap
25.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.18B | -273.00M | -11.12% |
| Mar 31, 2025 | 2.46B | -59.00M | -2.35% |
| Mar 31, 2024 | 2.51B | 482.00M | 23.72% |
| Mar 31, 2023 | 2.03B | -71.00M | -3.38% |
| Mar 31, 2022 | 2.10B | -154.00M | -6.82% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3-D Matrix | 11.92B |
| RaQualia Pharma | 3.90B |
| Heartseed | 3.03B |
| ReproCELL | 2.30B |
| AnGes | 962.00M |
| Stella Pharma | 323.00M |
| Cuorips | 128.00M |
| Healios K.K. | 59.00M |